Award
National Cancer Institute 11404787
Targeting FOXA2/AP-1 axis to overcome lineage plasticity and therapy resistance in castration-resistant prostate cancer
Recipient
University of Massachusetts Boston (implied by the principal investigator's affiliation)
Award Amount
$418,610.00
Ceiling
$418,610.00
Awarded
January 09, 2026
Identifier
11404787
A research award by the National Cancer Institute to study and develop therapies targeting the FOXA2/AP-1 axis in castration-resistant prostate cancer, with a total funding of $418,610 over five years.
Description
Research project funded by the National Cancer Institute focusing on prostate cancer. The project aims to elucidate mechanisms of cellular identity shifts and develop combination therapies targeting the FOXA2/AP-1 axis to overcome lineage plasticity and therapy resistance in castration-resistant prostate cancer. The project duration is from February 21, 2025, to January 31, 2030.